Drug intelligence / Profile preview

BCX-4678

Development stage: Discontinued
Lead developer: BioCryst Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BCX-4678 is a small molecule inhibitor of the hepatitis C virus (HCV) polymerase enzyme, developed by BioCryst Pharmaceuticals. Identified as a clinical candidate in the mid-2000s, the compound was designed to interfere with the viral replication process by targeting the NS5B RNA-dependent RNA polymerase. While it was advanced through preclinical testing with the intent of filing an Investigational New Drug (IND) application in 2006, the program did not progress to late-stage clinical development and is no longer active in the company's pipeline.

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on BCX-4678.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCX-4678.

Explore the full profile